Clinical trial Recruiting at 1 site Observational Ages 18 and up

Observational study on intracerebral hemorrhage in hospitalized adults

Official title: A Prospective Observational Cohort Study in Chinese Patients With Primary Intracerebral Hemorrhage

Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT04707105 · Data updated 2026-11-12

This study is trying to learn more about adults in the hospital with brain bleeding to better understand their treatment options and outcomes.

More Intracerebral Hemorrhage trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment856 (estimated)
SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine
Academic / other
Locations1 site (Hangzhou, Zhejiang)
StatusRecruiting
StartedDecember 29, 2020
Main results expectedDecember 2025
Study endsDecember 2026
Registry record updatedMarch 18, 2021
Trial IDNCT04707105 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are hospitalized adults over 18 years old diagnosed with primary intracerebral hemorrhage.

Probably not a fit

Patients with secondary intracerebral hemorrhage or those who cannot undergo necessary assessments will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to gather contemporary data on the prevalence, characteristics, risk factors, and prognosis of hospitalized adult patients in China suffering from primary intracerebral hemorrhage (ICH). It is a prospective, observational cohort study that will analyze various aspects of ICH, including treatment approaches and cost-effectiveness. The goal is to enhance understanding of this serious condition, which has high mortality rates and limited effective treatments. By focusing on a specific patient population, the study seeks to provide valuable insights into ICH management.

Why it matters

Potential benefit: If successful, this study could lead to improved risk stratification and treatment strategies for patients with intracerebral hemorrhage.

How similar studies have gone: While there have been studies on intracerebral hemorrhage, this specific observational approach focusing on the Chinese population may provide novel insights.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Hospitalized patients over 18 years old of primary intracerebral hemorrhage.

Exclusion Criteria:

1. patients of secondary intracerebral hemorrhage,such as hemorrhagic transformation of ischemic stroke, aneurysmal, cavernomas, arterio- venous malformations, central venous thrombosis, trauma-related, or tumor.
2. isolated intraventricular hemorrhage or subarachnoid hemorrhage pregnant patients;
3. surgical evacuation of hematoma;
4. unavailability to get complete blood cell samples and presenting contraindications or refusal to MRI
5. patients cannot be followed up for any reasons.
6. patients death in 24 hours
7. pregnant patients

Where it's running

  • 2nd Affiliated Hospital, School of Medicine at Zhejiang University
    Hangzhou, Zhejiang, China
    Recruiting

Study contacts

  • Principal investigator: Feng Gao, MD,PhD — Second Affiliated Hospital, Zhejiang University, School of Medicine
  • Study coordinator: Feng Gao, MD,PhD
  • Email: 2202012@zju.edu.cn
  • Phone: 13588451471

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.